Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

823 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Among authors: cooper da. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. Markowitz M, et al. Among authors: cooper da. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15. doi: 10.1097/QAI.0b013e31802b4956. J Acquir Immune Defic Syndr. 2006. PMID: 17133211 Clinical Trial.
Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Steigbigel RT, et al. Among authors: cooper da. N Engl J Med. 2008 Jul 24;359(4):339-54. doi: 10.1056/NEJMoa0708975. N Engl J Med. 2008. PMID: 18650512 Free article. Clinical Trial.
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams. Eron JJ, et al. Among authors: cooper da. Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7. Lancet Infect Dis. 2013. PMID: 23664333 Free PMC article. Clinical Trial.
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. Hoen B, et al. Among authors: cooper da. Clin Infect Dis. 2007 Aug 1;45(3):381-90. doi: 10.1086/519428. Epub 2007 Jun 26. Clin Infect Dis. 2007. PMID: 17599319 Free article.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Cooper DA, et al. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978. N Engl J Med. 2008. PMID: 18650513 Free article. Clinical Trial.
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Yeni P, Strohmaier KM, Rodgers AJ, Barnard RJ, Nguyen BY, Teppler H; BENCHMRK Study Teams. Eron JJ, et al. Among authors: cooper da. Antivir Ther. 2015;20(3):307-15. doi: 10.3851/IMP2912. Epub 2014 Oct 27. Antivir Ther. 2015. PMID: 25350973 Free PMC article. Clinical Trial.
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ Jr, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP. Nelson M, et al. Among authors: cooper da. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):404-12. doi: 10.1097/01.qai.0000185314.56556.c3. J Acquir Immune Defic Syndr. 2005. PMID: 16280694 Clinical Trial.
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, Steinhart CR, Trottier B, Walmsley SL, Workman C, Mukwaya G, Kohlbrenner V, Dohnanyi C, McCallister S, Mayers D; RESIST-1 Study Group. Gathe J, et al. Among authors: cooper da. Clin Infect Dis. 2006 Nov 15;43(10):1337-46. doi: 10.1086/508353. Epub 2006 Oct 17. Clin Infect Dis. 2006. PMID: 17051503 Clinical Trial.
823 results